ANNALS OF ONCOLOGY
9 publications · 131 citations
Publications
| Title | Year | Author | Citations |
|---|---|---|---|
|
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
|
2025 | Al-Batran, S-e., Wainberg, Z. A., Muro, K. +17 | 4 |
|
A mobile app-supported orem's care effect for gastrointestinal cancer patients' symptom management and self-care ability: A quasi-experimental study
|
2025 | Yasar, Y. Ciraci, Tan, M. | 0 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Janjigian, Y. Y., Kawazoe, A., Bai, Y. +17 | 38 |
|
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
|
2024 | Sezgin, Y., Karhan, O., Urakci, Z. +14 | 1 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Rha, S. Y., Kawazoe, A., Bai, Y. +17 | 0 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Janjigian, Y. Y., Al-Batran, S-E., Wainberg, Z. A. +17 | 72 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Oh, D-Y., Janjigian, Y. Y., Al-Batran, S-E. +17 | 11 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
|
2023 | Janjigian, Y. Y., Kawazoe, A., Bai, Y. +17 | 5 |
|
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
|
2023 | Rha, S. Y., Kawazoe, A., Bai, Y. +17 | 0 |